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Streptococcus pneumoniae is the most common bacterial cause of community-acquired meningitis worldwide. Despite optimal
antibiotic therapy and supportive care, the mortality of this condition remains very high at 20–30% in the developed world and
over 60% in under-resourced hospitals. In developed countries, approximately half of the survivors suﬀer intellectual impairment,
hearing loss, or other neurological damage. There is an urgent need for more information about the mechanisms of brain damage
and death in pneumococcal meningitis so that new treatments can be designed. Using proteomic techniques and bioinformatics,
the protein content of cerebrospinal fluid can be examined in great detail. Animal models have added greatly to our knowledge
of possible mechanisms and shown that hippocampal apoptosis and cortical necrosis are distinct mechanisms of neuronal death.
The contribution of these pathways to human disease is unknown. Using proteomic techniques, neuronal death pathways could
be described in CSF samples. This information could lead to the design of novel therapies to minimize brain damage and lower
mortality. This minireview will summarize the known pathogenesis of meningitis, and current gaps in knowledge, that could be
filled by proteomic analysis.
Copyright © 2009 U. R. Goonetilleke et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Clinical Problem of Meningitis
Infection of the membranes surrounding the central nervous
system (meninges) results in meningitis. Streptococcus pneu-
moniae, an ovoid gram-positive bacterium [1], is the most
common cause of bacterial meningitis [2]. Pneumococci are
able to colonise the nasopharynx without developing any
serious consequences. Pneumococcal carriage rates in young
children vary from over 40% in developed nations such as
USA to 87% in developing nations such as Gambia [3, 4].
Pneumococcal carriage rates in adults vary from approxi-
mately 10% in developed nations such as USA to 51% in
developing nations such as Gambia [5]. When pneumococci
spread to the sinuses, ear, lung, and blood stream, diseases
such as sinusitis, otitis media, pneumonia, and septicaemia
can result (Figure 1). As an example pneumococcal meningitis
in Malawi has a high fatality rate of 65% [6] and survivors
may develop long-term neurological sequelae, including
hearing loss and other focal neurological deficits [7].
2. Pathogenesis of Meningitis
Invasion of the central nervous system (CNS) by colonising
pneumococci follows an alteration in the balance between
the virulence of the bacteria and the defences of the patient.
Factors such as common colds or other upper respiratory
virus infections alter the lining of the respiratory tract
and allow bacteria to enter the bloodstream. Pneumococci
then actively translocate across intact endothelial layers [8]
by means of specific receptor binding and translocation.
Endothelial cells normally separate the blood from neuronal
tissue forming a protective blood-brain barrier (BBB).
The integrity of the BBB is compromised by apoptosis
of endothelial cells. The BBB breakdown allows further
invasion of cerebrospinal fluid (CSF) [9–11]. It has been
observed in some children that bacteria can translocate
directly from the nasopharynx into the CNS via olfactory
neurones [12]. A nonhaematogenous route has also been
demonstrated in animal models [13].
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Figure 1: When pneumococci spread to the sinuses, ear, lung, and blood stream, diseases such as sinusitis, otitis media, pneumonia, and
septicaemia can result. Invasion of the central nervous system (CNS) by colonising pneumococci follows an alteration in the balance between
the virulence of the bacteria and the defences of the patient. Factors such as common colds or other upper respiratory virus infections alter
the lining of the respiratory tract and allow bacteria to enter the bloodstream. Pneumococci then actively translocate across intact endothelial
layers by means of specific receptor binding and translocation. Endothelial cells normally separate the blood from neuronal tissue forming a
protective blood-brain barrier (BBB). The integrity of the BBB is compromised by apoptosis of endothelial cells. The BBB breakdown allows
further invasion of cerebrospinal fluid (CSF).
The host inflammatory response to the pneumococcus is
initiated by pneumococcal toxins such as pneumolysin and
hydrogen peroxide [14, 15]. Most of the tissue damage asso-
ciated with meningitis is caused by host responses including
the action of phagocytes, secreted granular toxins, cytokines
and leukotrienes, matrix metalloproteinases, and the direct
pressure eﬀect of cerebral oedema causing ischaemia [16].
In addition pneumococcal proteins have been shown to
contribute to neuronal cell death in animal models [17].
Neuronal cell death has been determined to occur via three
distinct pathways [18] which are illustrated in Figure 3.
(i) Classic caspase-3-dependent cell death which leads to
apoptosis or programmed cell death.
(ii) Caspase-3-independent cell death which leads to
pyknosis (irreversible condensation of chromatin in
the nucleus of a cell undergoing programmed cell
death or apoptosis).
(iii) Necrosis, the unnatural death of cells and living
tissue through cell swelling, chromatin digestion, and
disruption of the plasma membrane and organelles.
3. Neuronal Cell Death in the Hippocampus
Animal models have been used to determine the mechanism
of pneumococcal related neuronal apoptosis. In the rabbit
model of pneumococcal meningitis, hippocampal apoptosis
was found to be the predominant form of neuronal dam-
age [19, 20]. Inhibition of phosphorylcholine synthesis in
mitochondria of neurons in the hippocampal dentate gyrus
leads to mitochondrial release of apoptosis inducing factor
(AIF) which in turn causes pyknosis of the hippocampus.
In an adult mouse model both caspase-dependent and inde-
pendent forms of neuronal cell death have been described
in the dentate gyrus of adult mice [21]. Bacterial cell
wall products initiate mitochondrial release of cytochrome
c leading to classic toll-like receptor (TLR) dependent-
caspase-3 mediated apoptosis occurring more widely in the
brain. Infant rat models of pneumococcal meningitis showed
similar neuronal damage patterns to human disease [22, 23].
In the infant rat meningitis model, apoptosis and pyknosis
of neurons have been identified in the dentate gyrus of
the hippocampus (Figure 2). In humans apoptosis has been
identified in the dentate gyrus [24]. Apoptosis primarily
aﬀects the subgranular zone containing recently divided
immature neurons. Pyknosis occurs throughout the dentate
granular cell layer. Both mature and immature neurons are
aﬀected as a result [20].
4. Neuronal Cell Death in the Cortex by Necrosis
A feature of severe pneumococcal meningitis is ischaemic
damage of neurons in the ischaemic core of the cortex which
results in necrosis in addition to caspase-3 dependent cell
death in the ischemic core and penumbra [22, 25, 26].
Inflammation of the meninges leads to oxygen and glucose
deprivation of neuronal cells. The release of excitatory neuro-
transmitters from glutamatergic neurons leads to glutamate
receptor overactivation, Ca2+ influx and subsequent injury,
and eventually neuronal necrosis [27]. Neuronal necrosis and
neuronal apoptosis may share a final common path [28], that
is, the mitochondrial pathway as illustrated in Figure 3.
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Figure 2: The hippocampus is a part of the forebrain, located in the medial temporal lobe. The hippocampus is used in storing and
processing spatial information. In the rabbit model of pneumococcal meningitis, hippocampal apoptosis was found to be the predominant
form of neuronal damage. In humans, apoptosis and pyknosis have been identified in the dentate gyrus of the hippocampus. Apoptosis
primarily aﬀects the subgranular zone containing recently divided immature neurons. Pyknosis occurs throughout the dentate granular cell
layer.
5. Steroid Therapy
Most of the information that is known about inflammation
has come from animal models, in which neuronal injury
may be reduced by modulation of the inflammatory response
with steroid adjuvant therapy [29]. In developed nations,
steroid adjuvant therapy has been shown to reduce deaths in
some adults, particularly in patients with mild pneumococcal
meningitis [30]. On the other hand, a large paediatric trial
in Malawi demonstrated no benefit from steroids in children
with bacterial meningitis [31]. Further, a double blind, ran-
domised, placebo controlled trial of dexamethasone adjuvant
therapy in adults with bacterial meningitis in Malawi also
showed no advantage at 40 days [32]. The diﬀerence seen
between Europe and Malawi is likely to have resulted from
diﬀerences in the severity of the cases. There remains an
urgent need for novel adjuvant therapy in the treatment on
pneumococcal meningitis worldwide.
6. Potential for New Therapy
Critical pathways for new therapy should clearly target the
apoptotic and necrotic pathways. For example, citicholine
is an intermediate in the synthesis of phosphorylcholine
in mitochondrial and cell membranes. It has been shown
to prevent neuronal damage when given before and after
bacterial infection in animal models of meningitis, regardless
of the route of infection [15, 33]. Alternatively matrix met-
alloproteinase inhibitors could prevent blood brain barrier
damage. Matrix metalloproteinase (MMPs) are a family
of zinc-dependent endopeptidases that show aﬃnity to
diﬀerent components of the extracellular matrix. They have
been shown to play a role in the breakdown of the blood-
brain barrier and the facilitation of neuroinflammation in
bacterial meningitis [34]. In bacterial meningitis, MMPs may
contribute to the development of brain injury by both their
proteolytic activity on the extracellular matrix and their
ability to increase the levels of soluble TNF-α, a pivotal
element in the meningeal inflammatory process. TNF-α is a
strong stimulus for the release and activation of MMPs in the
brain [35, 36].
7. Critical Gaps in Knowledge
There are critical gaps in knowledge that need to be
addressed before new therapies can be implemented in
meningitis. In particular there is insuﬃcient data to link
human death in meningitis with the mechanisms observed
in animal models. High levels of CSF apoptosis proteins in
patients with neurological damage or death would provide
a basis for trials of citicholine. Alternatively, high levels of
MMP and MMP-related damage would provide a case for
the use of MMP inhibitors. Proteomics’ methods provide a
modern means of obtaining these pivotal data. Proteomics
is the qualitative and quantitative analysis of all expressed
proteins present in cells, tissues, or organisms at certain time
and under diﬀerent conditions [37].
The application of proteomics to CSF samples and serum
will allow the presence or absence of both high and low
abundant proteins to be associated with neurological damage
and death in meningitis. Proteomics’ approaches allow the
analysis of a large spectrum of host and pathogen proteins
but cannot yet be applied to the bacterial cell wall com-
ponents such as lipoteichioic acid (LTA) of pneumococcus.
These methods have already been applied in malaria and
tuberculosis but have not yet advanced to the treatment of
pneumococcal meningitis [38, 39].
8. Proteomic Methods That Can Be Applied to
CSF Analysis
A basic proteomic approach to meningitis will involve the
comparison of protein expression in normal and disease
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Figure 3: (a) The cell wall of S. pneumoniae has a diverse protein population. Proteins such as pneumolysin can trigger apoptosis on entering
cells by destruction of the mitochondria. In addition oxidising components such as hydrogen peroxide can trigger apoptosis and necrosis.
(b) The host immune response will most likely be made up of complement and cytokines which can activate transmembrane death receptors
such as Fas. This will cause receptors to aggregate together on the cell surface leading to apoptosis. The adaptor protein Fas-associated death
domain protein (FADD) activates caspase-8, an initiator protein, to form a signal complex to directly activate caspase-3. Active caspase-8
can also cleave BID protein to tBID, which acts as a signal on the membrane of mitochondria to facilitate the release of cytochrome c in
the intrinsic pathway. The mitochondrial stress pathway is initiated when proapoptotic proteins in the cytoplasm, BAX, and BID stimulate
the rupture of the mitochondria. The release of mitochondrial content is aided by the protein BAK. In the caspase dependant pathway,
cytochrome c released from the mitochondria forms a complex in the cytoplasm with adenosine triphosphate (ATP) and apoptotic protease
activating factor-1 (Apaf-1). This complex activates caspase-9, an initiator protein. In return, the activated caspase-9 works together with
the complex of cytochrome c, ATP, and Apaf-1 to form an apoptosome, which in turn activates caspase-3, the eﬀector protein that initiates
degradation. The caspase independent pathway (pyknosis) is as a result of apoptosis inducing factor (AIF). The necrotic pathway is activated
in severe meningitis. Alterations in the concentration of cytoplasmic calcium could signal the mobilisation of executioner cathepsin proteases
and other hydrolases, through calpain activation. Calpains have been implicated in the activation of proapoptotic caspase proteases; hence
the later steps of necrosis correlate with the later steps of apoptosis.
CSF to identify aberrantly expressed proteins [37]. Proteomic
techniques applicable to CSF are either top-down, that is, a
“shotgun” approach to protein identification or bottom-up,
that is, the identification of proteins from the peptide spectra
of a digested protein [40, 41] as shown in Figure 4.
9. Top-Down Proteomics
2-Dimensional Polyacrylamide Gel Electrophoresis (2D
PAGE) with protein identification using mass spectrome-
try [42] involves the separation of proteins according to
isoelectric point and molecular weight. The proteins are
excised out of the gels and either directly interrogated
by mass spectrometry (true top down proteomics) or are
digested with specific enzymes prior to analysis using mass
spectrometry. The isoelectric point of a protein and their
mass aids identification of proteins and posttranslational
modified proteins can be identified through the position in
the gel at a comparatively low cost. However 2D PAGE is
slow, and high-abundant proteins in the gel can confound
small proteins.
Protein microarrays consist of diﬀerent protein binding
molecules, for example, antibodies spotted at separate iden-
tifiable locations on a chip made from glass or silicone to
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Figure 4: (a) Proteins from mixtures are analysed using 2D PAGE followed by mass spectrometry. The identification of proteins is from
the spectra produced from the peptides of the digested proteins which provide a unique fingerprint from the peptides. Protein microarrays
consist of diﬀerent protein binding molecules, for example, antibodies at separate locations on a chip made from glass or silicone to capture
molecules to detect proteins from cell lysate solutions. The proteins can be visualised using a fluorometric or colorimetric analysis or the
spots can be analysed by mass spectrometry. (b) Multidimensional liquid chromatography mass spectrometry (LC-MS) involves digestion of
a complex protein sample initially using a strong cation exchange (SCX) column. The resulting peptides are separated by LC into fractions.
The resulting fractions are separated further using a reversed-phase (RP) column and characterized by mass spectrometry using shotgun
sequencing of the peptides.
detect proteins from cell lysate solutions [43]. This technique
has high sensitivity and can simultaneously analyse thou-
sands of proteins within a single experiment. Antibody spe-
cific profiling allows analysis of complex protein mixtures;
however this limits the technique to the detection of specific
targets and does not give a complete view of the proteins
involved in a process.
10. Bottom-Up Approaches
Multidimensional liquid chromatography mass spectrome-
try (LC-MS) involves digestion of a complex protein sample.
The resulting peptides are separated by chromatography into
fractions. The resulting fractions are separated further by
chromatography and characterized by mass spectrometry
using shotgun sequencing of the peptides, that is, the peptide
fractions are reassembled to give the overall sequence to
generate protein lists. This technique is almost entirely
automated and has increased sensitivity to enhance the
detection of low-abundance proteins. It has a greater success
in the identification of proteins in very complex mixtures
[42, 44, 45]. However, analysis times can be long, and the
resulting data is complex. Also high abundance proteins tend
to confound smaller proteins in the analysis.
11. Western Blotting
An alternative protein analysis technique is western blotting
in which proteins in CSF can be confirmed using specific
antibodies. This technique allows specific targets to be
compared between sample groups. It relies on previous
identification of proteins of interest.
12. Nonprotein Techniques
Glycan structures present on the cell wall such as lipotei-
chioic acid (LTA) and peptidoglycan (PG) play an important
role in inflammation but are not accessible to proteomic
approaches. Glycans can be measured using specialist tech-
niques for example the silkworm larvae (SLP) test was
developed to analyse PG in CSF [46]. Similarly LTA can be
measured using an enzyme immunoassay [47].
13. Host and Pathogen Proteins
Proteomic comparisons of infected and normal CSF can be
expected to diﬀer in the concentration of both pneumococcal
proteins and host proteins. Identification of pneumococcal
proteins associated with poor outcome may suggest either
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Table 1: The cell wall of S. pneumoniae has a diverse protein population, and pathogenic expression of pneumoccal proteins are associated
with adherence to and colonisation of mucosal surfaces, resistance to specific and nonspecific host defences, penetration and invasion of
host tissues, and generation of tissue damage mediated either directly by toxins or indirectly via inflammatory responses.
Protein Description Action References
LytA
Enzyme required during
cell division
Hydrolyses amide bonds between muramic acid
and L-Alanine residues
[48, 49]
PspA
Ranges from 67–99 kDa
in size. Anchored to the
outer layer of the plasma
membrane
Reduces complement mediated clearance and
phagocytosis of S. pneumoniae. Inhibits
complement activation, thereby limiting
opsonisation of pathogens by complement
protein 3 (C3)
[50]
Pneumococcal
histidine triad
(Pht)
Novel family of cell sur-
face-exposed pneumoc-
occal proteins
Consists of PhtA, PhtB, PhtD, and PhtE. PhtB
and PhtE. Induces antibodies capable of
protecting mice against pneumococcal sepsis
and death
[51, 52]
PspC
Surface protein choline
binding domain has 90%
homology to PspA
Binds to the polymeric immunoglobulin
receptor and mediates invasion across human
nasopharyngeal epithelial cells
[53, 54]
Neuraminidases,
for example, NanA
and NanB
Cleaves terminal sialic
acid residues from a wi-
de variety of glycolipids,
glycoproteins, and oligo-
saccharides
The precise role of NanA in pneumococcal
disease is unknown. The relative contribution of
NanB to disease has not been reported in either
a sepsis or pneumonia model
[55, 56]
Heat shock
proteins
A highly conserved set of
proteins
Heat stress proteins are produced after
penetration from the nasal mucosa (30 to 34◦C)
into the blood and/or meninges (37◦C)
[39]
Hyaluronate lyase
(Hyal)
Covalently linked to the
cross-bridges of the cell
wall peptidoglycan
Degrades essential components of the host’s
extracellular matrix (ECM), hyaluronan (HA),
unsulfated chondroitin (CH), and certain
chondroitin sulfates (CHSs)
[57]
Pneumococcal
surface antigen A
(PsaA)
34.5 kDa protein covale-
ntly anchored to the cell
membrane
Belongs to an ATP binding cassette-(ABC-) type
transport system and constitutes the
extracellular component responsible for solute
(metal) binding
[58]
Pneumolysin
(Hemolysin or Ply)
53-kDa protein
Binds to membrane cholesterol and inserts the
toxin into the lipid bilayer. Induces leakage of
solutes
[59]
Penicillin-binding
proteins (PBPs)
S. pneumoniae carry a re-
latively simple set of six
PBPs
Catalyse the polymerisation of glycan chains and
transpeptidation of pentapeptidic moieties
within the structure of the peptidoglycan
[60]
Pneumococcal iron
uptake (Piu) and
iron acquisition
(Pia)
Lipoprotein components
of iron ABC transport
systems
Essential for iron uptake. Pia is the dominant
iron transporter. PiuA and PiaA have been
shown to be present in all pneumococcal species
[61]
therapeutic possibilities or vaccine candidates. Host pro-
teins associated with poor outcome may suggest pathways
amenable to immunomodulation or therapeutic interven-
tion.
14. Pneumococcal Proteins
The cell wall of S. pneumoniae has a diverse protein pop-
ulation, and pathogenic expression of pneumoccal proteins
is associated with adherence to and colonisation of mucosal
surfaces, resistance to specific and nonspecific host defences,
penetration, and invasion of host tissues, and generation of
tissue damage mediated either directly by toxins or indirectly
via inflammatory responses as summarised in Table 1. All the
proteins listed in Table 1 have been described in experimental
studies including animal models of meningitis and have been
found to exhibit an eﬀect on inflammation, and toxicity for
example N-acetylmuramoyl-L-alanine-amidase (LytA) is an
autolytic enzyme required during cell division. Its role in
pneumococcal meningitis is unknown but has been shown in
various animal models to mediate toxicity and inflammation
[48]. Proteins such as pneumolysin can stimulate the host
response and also enter cells though pore formation. It
has the ability to trigger apoptosis on entering cells by
destruction of the mitochondria [48]. In addition oxidising
components such as hydrogen peroxide can also trigger
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Table 2: The host immune response will most likely make up the majority of proteins present in the CSF because these proteins will include
host immune response factors such as complement and cytokines as well as specific immunoglobulins and proteins from serum leaking to
the CSF as a result of the blood brain barrier breakdown.
Protein Description Action References
Complement
components, for
example, C3b,
iC3b, or C4b
(CR1, CR3)
Consists of a number of
small proteins found in the
blood, normally circulating
as inactive zymogens
Help to clear pathogens from an
organism
[62]
IL-6
A proinflammatory cytok-
ine
Secreted by T cells and
macrophages to stimulate
immune response to trauma,
leading to inflammation
[63]
Interleukin-1
(IL-1)
A superfamily consisiting of
IL-1α, IL-1β, and the IL-
1 receptor antagonist (IL-
1RA)
They control lymphocytes. IL-1α
and IL-1β are produced by
macrophages, monocytes, and
dendritic cells
[64]
IgG
The most abundant imm-
unoglobulin. Equally dis-
tributed in blood and in
tissue liquids
Activates complement (classic
pathway), opsonization for
phagocytosis, and neutralisation
of their toxins
[65]
Table 3: Poteins associated with the apoptotic pathway could potentially be discovered in the CSF after cell death. The levels of these proteins
can be expected to increase during pneumococcal meningitis as a result of both the inflammatory response and the release of pneumococcal
proteins.
Protein Description Action References
Cytochrome C (Cyt C)
A small heme protein found loosely
associated with the inner mem-
brane of the mitochondrion
Cause ER calcium release. The
overall increase in calcium triggers
a massive release of additional cyt
c, which then acts in the positive
feedback loop to maintain ER cal-
cium release through the inositol
3 phosphate receptors. This release
in turn activates caspase-9
[66]
Tumour necrosis factor (TNF-α)
TNF acts via the TNF receptor
(TNF-R) and is part of the extrinsic
pathway for triggering apoptosis
TNF-R associates with procaspases
through adapter proteins (FADD,
TRADD, etc.)
[67]
Caspases Proteases, which exist as inactive
proenzymes
Play essential roles in apopto-
sis (programmed cell death) and
inflammation
[10]
Fas
Ligand which associated with the
forms the Death Inducing Sig-
nalling Complex (DISC) upon lig-
and binding
Fas pathway is suﬃcient to induce
complete apoptosis in certain cell
types through DISC assembly and
subsequent caspase-8 activation
[68]
Fas-associated death domain protein (FADD)
An adaptor molecule that bridges
the Fas-receptor, and other death
receptors, to caspase-8 through its
death domain
Forms the death inducing sig-
nalling complex (DISC) during
apoptosis
[68]
BAX A proapoptotic member of the Bcl-
2 protein family
Activated Bax forms an oligomeric
pore in the outer membrane
[10]
Apoptosis inducing factor (AIF)
A flavoprotein found in the mito-
chondrial intermembrane space in
healthy cells
Essential for nuclear disassembly
in apoptotic cells
[10]
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apoptosis and necrosis. Both pneumolysin and autolysin
have been shown to play a crucial role in the pathogenesis of
pneumococcal meningitis in an adult rat model of meningitis
[69]. Neuraminidases are a group of enzymes which can
cleave terminal sialic acid residues from a wide variety of
glycan structures [55]. The pneumococcus produces two
distinct neuraminidases, N-acetylneuraminic acid (NanA)
and endo-β-1, 4-N-acetylglucosaminidase (NanB) [70, 71].
There are several conflicting publications on the precise
role of NanA in pneumococcal disease; however an Otitis
media chinchilla model that revealed that NanA-deficient
pneumococci are significantly less able to colonise and persist
in the nasopharynx and middle ear than NanA-suﬃcient
wild-type pneumococci [56]. The relative contribution of
NanB to disease has not been reported in either a sepsis or
pneumonia model.
15. Host Proteins
The host immune response will most likely make up the
majority of proteins present in the CSF because these
proteins will include host immune response factors such as
complement and cytokines as well as specific immunoglob-
ulins and proteins from serum leaking to the CSF as a result
of the blood brain barrier breakdown (Table 2). These will
include signalling molecules such as tumour necrosis factor
alpha (TNF-α) [72], Fas and Fas-associated death domain
(FADD) protein, (Table 3) [68]. These proteins can lead
to apoptosis through activation of transmembrane death
receptors, such as Fas which causes receptors to aggregate
together on the cell surface. This activates the adaptor protein
Fas-associated death domain (FADD) protein, which in turn
activates caspase-8, an initiator protein, to form a signal
complex. This complex is now able to directly activate
caspase-3, an eﬀector protein, to initiate degradation of the
cell. Active caspase-8 can also cleave BID protein to tBID,
which acts as a signal on the membrane of mitochondria to
facilitate the release of cytochrome c in the intrinsic pathway.
The mitochondrial stress pathway is initiated when a stress
signal is activated, proapoptotic proteins in the cytoplasm,
BAX, and BID stimulate the rupture of the mitochondria.
The release of mitochondrial content is aided by the protein
BAK. In the caspase dependant pathway, cytochrome c
released from the mitochondria forms a complex in the
cytoplasm with adenosine triphosphate (ATP) and apoptotic
protease activating factor-1 (Apaf-1). This complex activates
caspase-9, an initiator protein. In return, the activated
caspase-9 works together with the complex of cytochrome
c, ATP, and Apaf-1 to form an apoptosome, which in
turn activates caspase-3, the eﬀector protein that initiates
degradation. The caspase independent pathway (pyknosis)
is a result of apoptosis inducing factor (AIF). The necrotic
pathway is activated in severe meningitis. Alterations in the
concentration of cytoplasmic calcium signal the mobilisation
of executioner cathepsin proteases and other hydrolases,
through calpain activation. Calpains have been implicated
in the activation of proapoptotic caspase proteases; hence
the later steps of necrosis correlate with the later steps of
apoptosis.
Proteomic analysis of CSF will allow dominant pathways
to be determined and the relative importance of apoptosis
and necrosis to be estimated in patients and neurological
damage.
16. Conclusion
A novel therapy is needed to improve outcome in meningitis.
Animal models that suggest mechanism of neuronal injury
are amenable to therapy. Critical information is still needed
to move from animal models into human trials. This pivotal
information could be provided by proteomic analysis of CSF.
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